Literature DB >> 12906375

Clinical utility of bone markers in the evaluation and follow-up of osteoporotic patients: why are the markers poorly accepted by clinicians?

J J Stepan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12906375     DOI： 10.1007/BF03345203

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  27 in total

Review 1.  Prediction of bone loss in postmenopausal women.

Authors:  J J Stepan
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

2.  Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.

Authors:  P Garnero; E Sornay-Rendu; B Claustrat; P D Delmas
Journal:  J Bone Miner Res       Date:  2000-08       Impact factor: 6.741

3.  Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting.

Authors:  P Qvist; S Christgau; B J Pedersen; A Schlemmer; C Christiansen
Journal:  Bone       Date:  2002-07       Impact factor: 4.398

4.  Biochemical indices of bone turnover and the assessment of fracture probability.

Authors:  O Johnell; A Odén; C De Laet; P Garnero; P D Delmas; J A Kanis
Journal:  Osteoporos Int       Date:  2002-07       Impact factor: 4.507

5.  Removal of osteoclast bone resorption products by transcytosis.

Authors:  J Salo; P Lehenkari; M Mulari; K Metsikkö; H K Väänänen
Journal:  Science       Date:  1997-04-11       Impact factor: 47.728

Review 6.  Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy.

Authors:  B L Riggs; L J Melton; W M O'Fallon
Journal:  Bone       Date:  1996-03       Impact factor: 4.398

7.  Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis.

Authors:  J J Stĕpán; J Vokrouhlická
Journal:  Clin Chim Acta       Date:  1999-10       Impact factor: 3.786

8.  Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.

Authors:  P Ravn; B Clemmesen; C Christiansen
Journal:  Bone       Date:  1999-03       Impact factor: 4.398

9.  The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women.

Authors:  N H Bjarnason; K Bjarnason; C Hassager; C Christiansen
Journal:  Bone       Date:  1997-02       Impact factor: 4.398

10.  Geographic differences in bone turnover: data from a multinational study in healthy postmenopausal women.

Authors:  F J Cohen; S Eckert; B H Mitlak
Journal:  Calcif Tissue Int       Date:  1998-10       Impact factor: 4.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.